Treatment of Chronic Thyroid Eye Disease With MHB018A

Conditions

• Thyroid Eye Disease, TED

Eligibility Criteria

Sex

ALL

Age

18 Years - 75 Years

Healthy Volunteers

Not accepted

Interventions

• MHB018A injection — DRUG
  MHB018A 450mg for subcutaneous injection once every 4 weeks (Q4W)
• MHB018A injection Placebo — DRUG
  6 subcutaneous injections of MHB018A placebo once every 4 weeks (q4w)

Study Details

The primary objective of this study is to evaluate the efficacy of MHB018A injection compared with placebo in participants with chronic moderate-to-severe TED.

Key Dates

First listed

Jun 2, 2026

Start date

Sep 24, 2026

Status verified

Oct 2026

Primary completion

Jul 31, 2028

Completion

Jul 31, 2029

Study Design

Enrollment

135 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: MHB018A Injection
  subcutaneous injections of MHB018A injection, 450mg once every 4 weeks (q4w).
• Placebo Comparator: MHB018A Injection Placebo
  subcutaneous injections of MHB018A placebo once every 4 weeks (q4w)

Primary Outcome Measure

Proptosis response rate at Week 24 [ Time Frame: Week 24 ]

Central Contacts

• CMO/ Senior Vice President of R&D
  86 0571-86963293
  [email protected]

Locations (1)

Find similar trials in Coral Gables, FL

Related Studies

• Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study
  PHASE3 · Recruiting · Minghui Pharmaceutical (Hangzhou) Ltd · Coral Gables, Florida
• Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)
  PHASE3 · Recruiting · Sling Therapeutics, Inc. · Las Vegas, Nevada